MALLINCKRODT QUALITY CONTROL PROCEDURES FOR BULK ACETAMINOPHEN INADEQUATE
This article was originally published in The Tan Sheet
Executive Summary
MALLINCKRODT QUALITY CONTROL PROCEDURES FOR BULK ACETAMINOPHEN INADEQUATE at the company's Raleigh, N.C. facility, FDA charged in Nov. 18 warning letter. Mallinckrodt has "failed to implement appropriate quality controls for the testing of finished acetaminophen prior to release for distribution," the letter maintains. The bulk acetaminophen was intended for incorporation into a finished product in combination with hydrocodone bitartrate.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning